Circulating pneumococcal specific plasma and memory B cells in the elderly two years after pneumococcal conjugate versus polysaccharide vaccination

Vaccine

Volumn 28, Issue 42, 2010, Pages 6915-6922

  Baxendale, Helen E ^a,b   Johnson, Marina ^b   Keating, Sheila M ^b   Ashton, Lindsey ^b   Burbidge, Polly ^b   Woodgate, Sarah ^b   Southern, Jo ^c   Miller, Elizabeth ^c   Goldblatt, David ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Antibody; B cell; Conjugate vaccine; Elderly; ELISpot; Memory; Pneumococcus; Vaccine

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PNEUMOCOCCUS VACCINE;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GERIATRIC PATIENT; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; MALE; MEMORY CELL; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SUPERNATANT; VACCINATION;

AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; B-LYMPHOCYTES; COHORT STUDIES; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; VACCINES, CONJUGATE;

EID: 77956880129     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.004     Document Type: Article

References (46)

1. Melegaro A., Edmunds W.J., Pebody R., Miller E., George R. The current burden of pneumococcal disease in England and Wales. J Infect 2006, 52(January (1)):37-48.
2. Fedson D.S., Scott J.A. The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known. Vaccine 1999, 17(Suppl. 1 (July)):S11-S18.
3. World Health Organization 23-valent pneumococcal polysaccharide vaccine [position paper]. Wkly Epidemiol Rec 2008, 83:373-384.
4. Moberley S.A., Holden J., Tatham D.P., Andrews R.M. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008, (1). CD000422.
5. Bader M.S. Immunization for the elderly. Am J Med Sci 2007, 334(December (6)):481-486.
6. Konradsen H.B. Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons. Clin Infect Dis 1995, 21(3):616-620.
7. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group [see comments]. Pediatr Infect Dis J 2000, 19(March (3)):187-195.
8. Pavia M., Bianco A., Nobile C.G., Marinelli P., Angelillo I.F. Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis. Pediatrics 2009, 123(June (6)):e1103-e1110.
9. de Roux A., Schmoele-Thoma B., Siber G.R., Hackell J.G., Kuhnke A., Ahlers N., et al. Comparison of Pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008, 46(April (7)):1015-1023.
10. Ridda I., Macintyre C.R., Lindley R., Gao Z., Sullivan J.S., Yuan F.F., et al. Immunological responses to pneumococcal vaccine in frail older people. Vaccine 2009, 27(March (10)):1628-1636.
11. Miernyk K.M., Butler J.C., Bulkow L.R., Singleton R.J., Hennessy T.W., Dentinger C.M., et al. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age. Clin Infect Dis 2009, 49(July (2)):241-248.
12. Goldblatt D., Southern J., Andrews N., Ashton L., Burbidge P., Woodgate S., et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009, 49(November (9)):1318-1325.
13. Buisman A.M., de Rond C.G., Ozturk K., Ten Hulscher H.I., van Binnendijk R.S. Long-term presence of memory B-cells specific for different vaccine components. Vaccine 2009, 28(December (1)):179-186.
14. Baxendale H.E., Keating S.M., Johnson M., Southern J., Miller E., Goldblatt D. The early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly. Vaccine 2010, (May).
15. Wernette C.M., Frasch C.E., Madore D., Carlone G., Goldblatt D., Plikaytis B., et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol 2003, 10(July (4)):514-519.
16. Concepcion N.F., Frasch C.E. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001, 8(March (2)):266-272.
17. World Health Organization Training manual for enzyme linked immunosorbent assay for the quantitation of Streptococcus pneumoniae serotype specific IgG (Pn PS ELISA) 2010, Available at: http://www.vaccine.uab.edu/.
18. Crotty S., Aubert R.D., Glidewell J., Ahmed R. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods 2004, 286(March (1-2)):111-122.
19. Jessup C.F., Baxendale H., Goldblatt D., Zola H. Preparation of human-mouse heterohybridomas against an immunising antigen. J Immunol Methods 2000, 246(December (1-2)):187-202.
20. Lal G., Balmer P., Stanford E., Martin S., Warrington R., Borrow R. Development and validation of a nonaplex assay for the simultaneous quantitation of antibodies to nine Streptococcus pneumoniae serotypes. J Immunol Methods 2005, 296(January (1-2)):135-147.
21. Schlottmann S.A., Jain N., Chirmule N., Esser M.T. A novel chemistry for conjugating pneumococcal polysaccharides to Luminex microspheres. J Immunol Methods 2006, 309(February (1-2)):75-85.
22. Biagini R.E., Schlottmann S.A., Sammons D.L., Smith J.P., Snawder J.C., Striley C.A., et al. Method for simultaneous measurement of antibodies to 23 pneumococcal capsular polysaccharides. Clin Diagn Lab Immunol 2003, 10(September (5)):744-750.
23. Breitbart E., Wang X., Leka L.S., Dallal G.E., Meydani S.N., Stollar B.D. Altered memory B-cell homeostasis in human aging. J Gerontol A: Biol Sci Med Sci 2002, 57(August (8)):B304-B311.
24. Klinman N.R., Kline G.H. The B-cell biology of aging. Immunol Rev 1997, 160(December):103-114.
25. Chong Y., Ikematsu H., Yamaji K., Nishimura M., Nabeshima S., Kashiwagi S., et al. CD27(+) (memory) B cell decrease and apoptosis-resistant CD27(-) (naive) B cell increase in aged humans: implications for age-related peripheral B cell developmental disturbances. Int Immunol 2005, 17(April (4)):383-390.
26. Johnson S.A., Cambier J.C. Ageing, autoimmunity and arthritis: senescence of the B cell compartment-implications for humoral immunity. Arthritis Res Ther 2004, 6(4):131-139.
27. Colonna-Romano G., Aquino A., Bulati M., Di Lorenzo G., Listi F., Vitello S., et al. Memory B cell subpopulations in the aged. Rejuvenation Res 2006, 9(1):149-152.
28. Weksler M.E. Changes in the B-cell repertoire with age. Vaccine 2000, 18(February (16)):1624-1628.
29. Weksler M.E., Goodhardt M., Szabo P. The effect of age on B cell development and humoral immunity. Springer Semin Immunopathol 2002, 24(1):35-52.
30. Allman D., Miller J.P. B cell development and receptor diversity during aging. Curr Opin Immunol 2005, 17(October (5)):463-467.
31. Cancro M.P. B cells and aging: gauging the interplay of generative, selective, and homeostatic events. Immunol Rev 2005, 205(June):48-59.
32. Bondada S., Wu H., Robertson D.A., Chelvarajan R.L. Accessory cell defect in unresponsiveness of neonates and aged to polysaccharide vaccines. Vaccine 2000, 19(October (4-5)):557-565.
33. Aw D., Silva A.B., Palmer D.B. Immunosenescence: emerging challenges for an ageing population. Immunology 2007, 120(April (4)):435-446.
34. Kolibab K., Smithson S.L., Rabquer B., Khuder S., Westerink M.A. Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults: analysis of the variable heavy chain repertoire. Infect Immun 2005, 73(November (11)):7465-7476.
35. Kolibab K., Smithson S.L., Shriner A.K., Khuder S., Romero-Steiner S., Carlone G.M., et al. Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults. I. Antibody concentrations, avidity and functional activity. Immun Ageing 2005, June (2):10.
36. Romero-Steiner S., Musher D.M., Cetron M.S., Pais L.B., Groover J.E., Fiore A.E., et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis 1999, 29(August (2)):281-288.
37. Banerjee M., Mehr R., Belelovsky A., Spencer J., Dunn-Walters D.K. Age- and tissue-specific differences in human germinal center B cell selection revealed by analysis of IgVH gene hypermutation and lineage trees. Eur J Immunol 2002, 32(July (7)):1947-1957.
38. Barington T., Heilmann C., Andersen V. Quantitation of antibody-secreting cells in the blood after vaccination with Haemophilus influenzae type b conjugate vaccine. Scand J Immunol 1990, 31(4):515-522. [published erratum appears in Scand J Immunol 1990 July;32(1):59].
39. Clutterbuck E.A., Salt P., Oh S., Marchant A., Beverley P., Pollard A.J. The kinetics and phenotype of the human B-cell response following immunization with a heptavalent pneumococcal-CRM conjugate vaccine. Immunology 2006, 119(November (3)):328-337.
40. Odendahl M., Mei H., Hoyer B.F., Jacobi A.M., Hansen A., Muehlinghaus G., et al. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 2005, 105(February (4)):1614-1621.
41. Pihlgren M., Friedli M., Tougne C., Rochat A.F., Lambert P.H., Siegrist C.A. Reduced ability of neonatal and early-life bone marrow stromal cells to support plasmablast survival. J Immunol 2006, 176(January (1)):165-172.
42. Belnoue E., Pihlgren M., McGaha T.L., Tougne C., Rochat A.F., Bossen C., et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 2008, 111(March (5)):2755-2764.
43. Amanna I.J., Slifka M.K., Crotty S. Immunity and immunological memory following smallpox vaccination. Immunol Rev 2006, 211(June):320-337.
44. Bernasconi N.L., Traggiai E., Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002, 298(December (5601)):2199-2202.
45. Lanzavecchia A., Bernasconi N., Traggiai E., Ruprecht C.R., Corti D., Sallusto F. Understanding and making use of human memory B cells. Immunol Rev 2006, 211(June):303-309.
46. Mamani-Matsuda M., Cosma A., Weller S., Faili A., Staib C., Garcon L., et al. The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. Blood 2008, 111(May (9)):4653-4659.